AUTHOR INDEX

Ashley, G. W. 301

Crawshaw, L. 19

Denney, C. B. 227
Denney, R. M. 227

Fox, R. M. 31

Grahn, D. 19
Gyger, M. 227

Hill, J. A. 43
Hudson, J. B. 115

Karlsson, E. 259

Mbugua, P. M. 259
Ménez, A. 91
Momparler, R. L. 277, 287

Neu, H. C. 1

Quinn, R. P. 43

Rivard, G. E. 277
Rodríquez-Ithurralde, D. 259

Scharver, J. 43
Simpson, L. 19
Stubbe, J. 301

Wierenga, W. 67
Wollmuth, L. 19

SUBJECT INDEX

ABPP
  immune effector mechanisms 83
  interferon induction 78
Acycloguanosine 184, 187, 188
Acyclovir
  ^{125}I-labelled 49
  prodrugs 52
  radioimmunoassay 54
  radiolabelled 46, 47
Age and virus infection 131
AIDS 157
Amantadine 184, 185
Antibodies, virus effects 148–50
Anticholinesterase toxins 259–74
  amino acid composition 272–74
  atramine 270
  fasciculins 260–69, *see also* fasciculins
  mamba 259
  pharmacology 269, 270
Antiviral agents 183–89
  antibodies 55, 56
  antigen choice 54,55
  custom synthesis 50, 51
  diagnostic uses 60, 61
  disadvantages 183, 184
  ^{125}I-labelled 47
  labelling choice 45
  metabolism studies 56–60
    radiolabelling 58
  nomenclature 44, 45
  pyrimidinones 67–86
  radioactive synthesis 43–61
  radioimmunoassay 53–56
  renal clearance 58
  structures 184
  tritium labelled 47–49
Arabinosides 184–86
5-Aza-2′-deoxycytidine 287–97
  antileukemic activity 277, 278
  cell cycle effects 278, 291
  cell differentiation 283, 284, 292
  chemotherapy in animals 293, 294
  clinical response 280, 281
  combination 296
  cytotoxicity 290, 291
  DNA incorporation 289, 290
  DNA methylation 283, 290
  dose 279, 280
  gene activation 292
  immunosuppression 295
  leukaemia clinical trial 277–85
  mechanism of action 278, 279
  metabolism 288, 289
  mutagenicity 295
  pharmacokinetics 278, 282, 294
  resistance 293
  sensitivity tests 282
  structure 287
  toxicity 281, 282, 294, 295

6-β-Bromopenicillanic acid 12, 13

β-Bungarotoxin 105, 106

Cardiotoxins
  antigenic determinants 103
  immunological properties 102–104
Cell mediated immunity and animal viruses 150
Cholinesterase
  activity assay 264
  fasciculin inhibition 265–68
    partial 268, 269
  properties and fasciculin 263, 264
Clavulinic acid 7
  inactivation scheme 9
  structure 8
Combination chemotherapy, pyrimidinones 77
Complement and animal viruses 150
Creutzfeld–Jacob disease 169
Crotoxin 105

Dendrotoxins 106
Denucleotide triphosphate pools and inhibitors 31–41
Deoxyadenosine
  deoxynucleoside triphosphate pools 35
  M_1 subunit inhibitor 34–36
Deoxyadenosylcobalamin structure 302
Deoxyguanosine
  deoxynucleoside triphosphate pools 37
  M_1 subunit inhibition 37
Dinitrobenzamides, ribonucleotide reductase inhibition 40

Fasciculin
  amino acid composition 273
  cholinesterase binding 270–72
    Hill plots 271, 272
  cholinesterase effects 263, 264
  isolation 260–63

Genetics and virus infection 128, 129

HLA genes and virus infection 129, 130
Hydroxyurea
  deoxyribonucleoside triphosphate pools 39
  M_2 subunit inhibition 38–40

Immune modulators 195
Immune response and virus infection 130
Immunomodulation, pyrimidinones 78–83
Immunosuppression, viral 153–57
  scheme 153
  viruses causing 154–56
Inhibitors
  β-lactamase 1–16
  ribonucleotide reductase 31–41

Interferons
  antivirus action 149–53, 192, 193
  features 192
  inducers 194
  pyrimidone induction 78–83
  radiolabelled 52, 53

Kuru 169

β-Lactamase
  chromosomally mediated 5, 6
  classification 2–4
  clinical isolates 4, 5
  inactivators 13–15
  location 6
  plasmid mediated 4
  reactions 1, 2
β-Lactamase inhibitors *see also* individual compounds
  chemotherapy 1–16
  classes 6, 7
  clinical uses 14, 15
  effectiveness 7
  inactivation scheme 9
  specific 7–13
Liposomes, antiviral therapy 192
Livestock distribution, global 118

Methisazone 184–86
Monoamine oxidase A and B 227–51
  alteration effects 251
  brain differences 230, 231
    antisera 234
    expression 233
    immunological 233–37
    physical 231–33
  brain distribution 243–48
    neurones 247
    staining 246
  independence 248–51
  monoclonal antibodies 237–48
    MAO A 240–42
    MAO B 237–40
  properties 229, 230
  structural differences 242, 243
Monoclonal antibodies
  conjugates and animal viruses 190–92
    mechanisms of action 191
  curaremimetic toxin mapping 96–98
  monoamine oxidase A and B 237–48
    epitope sharing 242
Mutation, viruses 141–44

Olivanic acid 13, 14

Phagocytic cells, virus effects 147
6-Phenylpyrimidinone analogs, activities 85
Photochemotherapy
  photosensitizers 190
  virus 189, 190
Pyridine nucleotide analogs 184, 186, 187
Pyrimidinones *see also* interferon
  antitumour activity 74–78
  antiviral activity 69–74
    duration 73
  bioactivities 67–86
  clinical studies 86
  combination chemotherapy 77
  encephalomyocarditis infection 70
  structures 70, 71
  synthesis 68, 69

Radioimmunoassay, antiviral agents 53–56
Ribonucleotide reductase 301–27
  active site thiol inactivation 314
  adenosylcobalamin role 322–25
  2′-azido-2′-deoxynucleotide interactions 316–22
  2′-azidonucleotide inactivation 322
  binuclear iron assembly 325, 326
  classes 301–304
  cofactor role 325
  ClUDP inactivation 311–13
  2′-halo-2′-deoxynucleotide interactions 309–15
  intermediate 313
  manganese cofactor 304
  nucleotide reduction mechanism 304–309
    schemes 304–308
    stopped-flow studies 307
  N_3UDP inactivation scheme 316, 317
    N_3 fate 318
    new radical species 319–22
  radiolabelling 310, 311
  structure cofactor 302
Ribonucleotide reductase inhibitors
  deoxynucleotide triphosphate pools 31–41
  M1 subunit 32–38
  M2 subunit 38–40
  and modulators 31
Riboprobe system 173

Scrapie 169
Snake toxins 91–108, *see also* anticholinesterases, cardiotoxins
  amino acid sequences 92, 93
  antibody heterogeneity 95
  antigenic amino acids 93, 94
  curaremimetic neutralization 100–102
  epitope mapping 96–98
  mamba, types 259
  presynaptically acting 104–106
Stress and virus infection 132, 133
Sulfones 10, 11
  halogenated, structure 11
  structure 11

Taipoxin 105
Temperature *see also* thermoregulation
  central nervous regulation 19–28
Thermoregulation
  amphibians 25, 26
  birds 27, 28
  central nervous 19–28
  hypothalamic slice 22, 23
  mammals 27, 28
  neuroanatomy 23, 24
  neuronal mechanisms 20
  peripheral inputs 20, 21
  thermosensitivity 21, 22
  water breathing ectotherms 24, 25
Thymidine, M_1 subunit inhibition 32–34
Toxin γ
  antigenic determinants 98
  toxin–receptor dissociation 99, 100

Vaccines
  assessment 176, 182
  cloned proteins 177–79
  killed virus 176, 177
  live virus 176, 177
  passive immunization 180
  subunit 177
  supervaccines 180
  synthetic peptides 179, 180
  virus 175–95
Virus, animal 115–211
  african swine fever 198, 199
  attenuation and pathogenesis 133–35
  bluetongue 201, 202
  bovine leukemia 209, 210
  classification 116, 117
  control methods 175–95
  control points 121
    targets 125–27
  defective interfering 140, 141
  diagnostic methods 171–75
    new 172–74
    riboprobe 173
  economic aspects 118–20
  fish 206–209
  foot and mouth disease 196, 197
  herpes 202–204
  host effects 127–33, 145
    interactions 146
  immune system effects 146–53, *see also* immune system components
  immunosuppression 153–57
  influenza 204, 205
  murine cytomegalovirus
    hybridization probes 163
    immunosuppression 154
    pathogenesis and persistence 161–63
    reactivation 163–66
  mutation frequency 143, 144
  Newcastle disease virus 200, 201
  pathogenesis
    host factors 127–33
    viral factors 133–43
  persistence in host 157–71
    chronic infections 160–67
    factors affecting 170, 171
    latent 159, 160
    slow infections 167–70
    types of infection 158, 159
  rabies 197, 198
  replication 125–27
    schemes 126
    stages 126
  rhabdovirus, fish 206–208
  rinderpest 199, 200
  rotavirus 205, 206
  survival 144, 145
  taxonomy 115
  transmission 120–25
    between species 123, 124
    horizontal 121–23
    routes 121
    vertical 123
  vaccinia recombinant 181
  variability 135–39
    laboratory 139, 140
  vectors 124, 125
    climate effects 145
  vertebrate–anthropod cycles 120
  virulence and pathogenesis 133–35

YTR-H structure 12